Pinometostat is under clinical development by Epizyme and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pinometostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pinometostat overview

Pinometostat (EPZ-5676) is under development for the treatment of relapsed/refractory acute lymphocytic leukemia (ALL), acute myelocytic leukemia (AML), ovarian cancer and mixed lineage leukemia-rearranged leukemias (MLL-r) in pediatric and adult patients. The drug candidate is administered as intravenous infusion. It acts by targeting DOT1 like protein (DOT1L).

Epizyme overview

Epizyme is a biopharmaceutical company that discovers, develops, and markets novel epigenetic therapies for the treatment of cancer and other diseases. The company’s marketed products include Tazverik (tazemetostat), an oral, first-in-class, small-molecule inhibitor of EZH2 for the treatment of patients with metastatic or locally advanced epithelioid sarcoma and relapsed/refractory follicular lymphoma. Its pipeline products include tazemetostat for follicular lymphoma, DLBCL, epithelioid sarcoma and prostate cancer; PRMT 1 Inhibitor (GSK3368715) for solid tumors and DLBCL; and PRMT5 (GSK3368715) for solid tumors and blood cancer. The company develops products through a proprietary drug discovery platform and collaboration with other companies. Epizyme is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Pinometostat’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.